Pharmaceutical

Spectral Medical (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31, 2017. As quoted in the press release: Revenue for the three months ended December 31, 2017 was $918,000 compared …

Spectral Medical (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31, 2017.

As quoted in the press release:

Revenue for the three months ended December 31, 2017 was $918,000 compared to $806,000 for the same three-month period last year. Revenue for the year ended December 31, 2017 was $3,806,000 compared to $3,545,000 for the prior year, representing an increase of $261,000, or 7%.

Click here to read the full press release.

MARKETS

Markets
TSX18729.66-104.50
TSXV602.35-13.59
DOW31037.68+69.86
S&P 5003845.08+13.69
NASD11361.85+39.61
ASX6594.50-34.80

COMMODITIES

Commodities
Gold1744.78+4.38
Silver19.36+0.17
Copper3.49+0.08
Palladium1930.50+14.50
Platinum864.00+8.00
Oil99.00+0.47
Heating Oil3.46+0.05
Natural Gas5.56+0.05

DOWNLOAD FREE REPORTS

×